Evidence map›Paper›PMID 29673110›Full record

ArticleCancer medicine2018

Programmed death-ligand 1 expression in gastric cancer: correlation with mismatch repair deficiency and HER2-negative status.

Lei Wang, Qiongyan Zhang, Shujuan Ni, Cong Tan, Xu Cai, Dan Huang, Weiqi Sheng

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed, 3 pooled it
3.2field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 3 syntheses or guidelines pooled it, 62 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Article
  7. The influence ofFrontiers in immunology · 2025
    Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Review
  14. Article
  15. Observational
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Lei WangDepartment of Pathology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
Qiongyan ZhangDepartment of Pathology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.ORCID 0000-0001-9093-3418
Shujuan NiDepartment of Pathology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
Cong TanDepartment of Pathology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
Xu CaiDepartment of Pathology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
Dan HuangDepartment of Pathology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
Weiqi ShengDepartment of Pathology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
Shanghai Medical College of Fudan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gastric cancer (GC) is one of the most common malignancies. Immunotherapy is a promising targeted treatment. The immune regulatory programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) axis has been used as a checkpoint target for immunotherapy. Currently, considerable discrepancies exist concerning the expression status of PD-L1 and its prognostic value in GC. We aimed to evaluate the expression rates of PD-L1 in GC, and further assess its relationship with mismatch repair (MMR), and human epidermal growth factor receptor 2 (HER2) status. We retrospectively collected 550 consecutive cases of GC in Fudan University Shanghai Cancer Center from 2010 to 2012. PD-L1, MMR protein, and HER2 status were detected by immunohistochemistry (IHC). Fluorescence in situ hybridization was further used in HER2 IHC 2+ cases. Cases with at least 1% membranous and/or cytoplasmic PD-L1 staining in either tumor cells (TCs) or tumor-infiltrating immune cells (TIICs) were considered as PD-L1 positive. The correlation between clinicopathological parameters, HER2, MMR, and PD-L1 expression status was determined using chi-squared tests. About 37.3% cases (205/550) showed PD-L1 expression in TCs and/or TIICs. 17.3% cases (95/550) showed PD-L1 expression in TCs, 34.5% (190/550) cases showed PD-L1 expression in TIICs. There were 45 deficient MMR (dMMR) cases (8.2%), which showed higher rates of PD-L1 expression compared with MMR-proficient carcinomas (60.0% vs. 35.2%, P = 0.001). HER2 was positive in 66 (12.0%) cases. The expression of PD-L1 occurred more frequently in HER2-negative group than HER2-positive cohorts (39.0% vs. 24.2%, P = 0.020). The survival analysis revealed that PD-L1 was not associated with prognosis. This study evaluated the association between the PD-L1 expression and a specific subgroup (dMMR and HER2-negative) in a large Asian cohort of GC. GC patients with dMMR and HER2-negative status exhibited higher PD-L1 expression rates. Our finding indicated that MMR and HER-2 status might be potential biomarkers for anti-PD-L1 therapy.

Indexed as

Gene Expression Regulation, NeoplasticB7-H1 AntigenBiomarkers, TumorCell Line, TumorDNA Mismatch RepairErb-b2 Receptor Tyrosine KinasesFemaleHumansImmunohistochemistryKaplan-Meier EstimateMaleNeoplasm GradingNeoplasm StagingPrognosisStomach NeoplasmsB7-H1 AntigenBiomarkers, TumorCD274 protein, humanERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesGastric cancerHER2mismatch repair deficiencyprogrammed death-ligand 1

Identifiers

PMID29673110
PMCPMC6010739
OpenAlexW2800088787

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.